Levetiracetam Tablet, Film Coated, Extended Release
Product Images NDC 63629-9847

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 63629-9847). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Clcr 2 (13)

Clcr 2 (13)
FDA Label Image

Clcr 2 (2)

Clcr 2 (2)
FDA Label Image

Levetiracretam Structural Formula (3)

Levetiracretam Structural Formula (3)
FDA Label Image

Figure 1 (4)

Figure 1 (4)
FDA Label Image

Figure 2 (5)

Figure 2 (5)
This is a statistical data comparison between a placebo group (N=111) and two different doses of immediate-release levetiracetam tablets (1000 mg/day, N=106 and 2000 mg/day, N=105). The percentage of patients in each group is shown. There is also a note stating that the results are statistically significant compared to the placebo.*
FDA Label Image

Figure 3 (6)

Figure 3 (6)
This text appears to be a table displaying percentages. It shows different percentages for different categories, possibly related to patients or medication. The table includes percentages ranging from 0% to 45%. There are also references to a placebo group and immediate-release levetiracetam tablets. The note at the bottom of the table states that some data is statistically significant compared to the placebo. The specific context or purpose of this table is not clear.*
FDA Label Image

Figure 4 (7)

Figure 4 (7)
This text appears to be a comparison of the effectiveness of a placebo versus immediate-release levetiracetam tablets. The percentages indicate different levels of effectiveness, with 44.6% being the highest. It also mentions that the immediate-release levetiracetam tablets were statistically significant compared to the placebo.*
FDA Label Image

Label (Lbl636299847)

Label (Lbl636299847)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.